Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder

Clinical Pharmacokinetics

Volumn 40, Issue 2, 2001, Pages 135-143

  Olsson, B ^a   Szamosi, J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DRUG METABOLITE; TOLTERODINE;

ADULT; ARTICLE; BLADDER DYSFUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; FEMALE; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED DRUG RELEASE;

EID: 0035071434     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140020-00005     Document Type: Article

References (31)

1. The patient with overactive bladder: Symptoms and quality of life issues
2. The overactive bladder: An overview for primary care health providers
3. Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity
4. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis
5. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder
6. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder
7. The mechanism of action of tolterodine
8. Pharmacokinetics and pharmacodynamics of tolterodine in man: A new drug for the treatment of urinary bladder overactivity
9. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine
10. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes
11. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine
12. Polymorphic hydroxylation of debrisoquine in man
13. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
14. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity
15. Serum protein binding of tolterodine and its major metabolites in humans and several animal species
16. Tolterodine in the treatment of overactive bladder: Analysis of the pooled phase II efficacy and safety data
17. Interactions affecting drug absorption
18. Food increases the bioavailability of tolterodine but not effective exposure
19. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population
20. Determination of tolterodine and the 5-hydroxymethyl metabolite in plasma, serum and urine using gas chromatography-mass spectrometry
21. Individual variation in first-pass metabolism
22. A computer simulation of the food effect: Transient changes in hepatic blood flow and Michaelis-Menten parameters as mediators of hepatic first pass metabolism and bioavailability of propranolol
23. Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: Evidence implicating substrate delivery rate as a determinant of presystemic drug interactions
24. Reduction of first-pass hepatic clearance of propranolol by food
25. Tolterodine oncedaily: Superior efficacy and tolerability in the treatment of the overactive bladder
26. Multiple dose pharmacokinetics of a new once daily, extended-release tolterodine formulation versus immediate release tolterodine